A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib.

Trial Profile

A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms PAZOGIST
  • Most Recent Events

    • 05 Apr 2016 Primary endpoint has been met. (Progression-free survival), as per article published in the Lancet Oncology.
    • 05 Apr 2016 Results published in the Lancet Oncology
    • 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top